Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
N2OFF ( (NITO) ) just unveiled an update.
On January 26, 2026, N2OFF’s board approved changing the company’s name to Nexentis Technologies Inc. and its Nasdaq ticker to NXTS, with both changes and a related Nevada charter amendment taking effect on February 26, 2026, without requiring shareholder approval and without altering stockholder rights or the existing CUSIP. The February 25, 2026 press release framed the rebranding as the culmination of a strategic pivot from cleantech to an AI- and data-driven mitochondrial biotech model following the October 20, 2025 acquisition of MitoCareX, positioning Nexentis to advance a precision oncology and inflammatory metabolic disease pipeline while treating its solar assets as non-core holdings.
The rebranding to Nexentis highlights the integration of MitoCareX’s MITOLINE-powered discovery engine, which has already produced in vitro evidence of anti-tumor activity and reduction of pro-inflammatory markers, supporting further development in markets expected to exceed $120 billion by 2030. Management expects the new identity to sharpen strategic focus around next-generation mitochondrial medicines, strengthen alignment with R&D priorities, and enhance the company’s appeal to partners and collaborators across the biotech and pharmaceutical sectors.
More about N2OFF
N2OFF, Inc., now rebranding as Nexentis Technologies Inc., is a drug discovery company focused on oncology and inflammatory metabolic diseases through its wholly owned subsidiary MitoCareX Bio Ltd., which targets the mitochondrial SLC25 protein family using its MITOLINE computational platform. The company also holds non-core investments in European RTB solar energy projects and controls about 98% of Save Foods Ltd., an Israeli post-harvest food treatment technology firm, reflecting a diversified but increasingly biotech-centered portfolio.
Average Trading Volume: 875,260
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.47M
Learn more about NITO stock on TipRanks’ Stock Analysis page.